Challenge
A biopharma startup risked delaying Phase 3 trials and funding because CMC teams lacked coordinated information. A 2,600-line schedule was difficult to use, assumptions were undocumented, and supply chain issues were not shared effectively.
Response
PMO Partners rebuilt communication across CMC and adjacent functions, created integrated but manageable timelines, and mapped handoffs. Risk registers, scenario planning, workshops, and weekly delivery sprints improved transparency and accountability.
Outcome
Durations between critical milestones, such as raw material ordering and drug product readiness, fell by 60%. The team manufactured clinical supply on time for Phase 3 and removed CMC from the critical path. At publication, development remained on track and investor funding was secure. The handoff included processes supporting continued collaboration and future planning.
An edited client story. Outcomes and figures describe the reported engagement, rather than a promise of results for another organization.